Wells Fargo analyst Derek Archila upgraded Kymera Therapeutics (KYMR) to Overweight from Equal Weight with a price target of $57, up from $38. The shares could trade up 75% in a bull case on KT-621’s Phase 1 update in the first half of 2025, the analyst tells investors in a research note. The firm says that even with Kymera’s year-to-date performance, the Street’s assigned value for KT-621 is still fairly conservative. It would be a buyer of the stock at these levels. Wells feels good about KT-621’s Phase1 safety and says the drug’s opportunity is substantial.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on KYMR:
- Kymera Therapeutics initiated with an Overweight at Stephens
- Kymera Therapeutics price target raised to $49 from $45 at Morgan Stanley
- Kymera Therapeutics price target raised to $52 from $45 at Guggenheim
- U.S. drugmakers shifting away from Chinese supply-chain partners, WSJ says
- Kymera Therapeutics Reports Q3 2024 Earnings and Strategic Shift
Questions or Comments about the article? Write to editor@tipranks.com